Piper Sandler Reaffirms “Overweight” Rating for Altimmune (NASDAQ:ALT)

Piper Sandler reaffirmed their overweight rating on shares of Altimmune (NASDAQ:ALTFree Report) in a research note released on Friday morning, Benzinga reports. Piper Sandler currently has a $25.00 price target on the stock.

A number of other brokerages have also recently commented on ALT. HC Wainwright reaffirmed a buy rating and set a $12.00 price objective on shares of Altimmune in a research note on Tuesday, May 14th. JMP Securities cut their price target on shares of Altimmune from $25.00 to $24.00 and set a market outperform rating on the stock in a research note on Friday, May 10th. B. Riley reaffirmed a buy rating and issued a $20.00 price objective on shares of Altimmune in a research report on Thursday, March 28th. Finally, Guggenheim downgraded Altimmune from a buy rating to a neutral rating in a research note on Monday, April 29th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of Moderate Buy and an average target price of $18.80.

Read Our Latest Analysis on ALT

Altimmune Trading Up 7.9 %

Shares of NASDAQ:ALT opened at $6.41 on Friday. The firm has a market capitalization of $454.47 million, a PE ratio of -4.03 and a beta of 0.11. Altimmune has a 1-year low of $2.09 and a 1-year high of $14.84. The business’s 50 day moving average is $7.12 and its 200-day moving average is $8.79.

Altimmune (NASDAQ:ALTGet Free Report) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.02. Altimmune had a negative return on equity of 46.96% and a negative net margin of 22,645.37%. The company had revenue of $0.01 million for the quarter. During the same quarter in the prior year, the company posted ($0.40) earnings per share. On average, sell-side analysts predict that Altimmune will post -1.34 EPS for the current year.

Institutional Trading of Altimmune

Large investors have recently bought and sold shares of the business. Timelo Investment Management Inc. raised its holdings in Altimmune by 2,597.0% in the 4th quarter. Timelo Investment Management Inc. now owns 809,095 shares of the company’s stock valued at $9,102,000 after buying an additional 779,095 shares during the last quarter. Knoll Capital Management LLC lifted its holdings in shares of Altimmune by 183.6% in the 1st quarter. Knoll Capital Management LLC now owns 567,219 shares of the company’s stock worth $5,774,000 after purchasing an additional 367,219 shares in the last quarter. Farallon Capital Management LLC grew its holdings in shares of Altimmune by 1,282.4% during the first quarter. Farallon Capital Management LLC now owns 470,000 shares of the company’s stock valued at $4,785,000 after buying an additional 436,000 shares during the last quarter. GSA Capital Partners LLP increased its holdings in Altimmune by 153.1% during the 3rd quarter. GSA Capital Partners LLP now owns 445,868 shares of the company’s stock worth $1,159,000 after purchasing an additional 269,676 shares in the last quarter. Finally, Lighthouse Investment Partners LLC purchased a new stake in shares of Altimmune in the fourth quarter worth approximately $4,493,000. 78.05% of the stock is owned by institutional investors and hedge funds.

Altimmune Company Profile

(Get Free Report)

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.

Featured Stories

Analyst Recommendations for Altimmune (NASDAQ:ALT)

Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.